世界の腎線維化治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Kidney Fibrosis Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z08023 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥494,160 (USD3,480)	▷ お問い合わせ
Multi User	￥741,240 (USD5,220)	▷ お問い合わせ
Corporate User	￥988,320 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、腎線維化治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腎線維化治療の種類別市場規模（アンジオテンシン変換酵素（ACE）阻害剤、ピルフェニドン、レニン阻害剤、アンジオテンシンII受容体遮断薬（ARB）、バソペプチダーゼ阻害剤）、用途別市場規模（慢性腎臓病、腎臓がん治療、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・腎線維化治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Merck and Co(US)、Pfizer Inc(US)、F. Hoffman-La Roche(Switzerland)、InterMune Inc(US)、Galectin Therapeutics(US)、La Jolla Pharmaceutical Company(US)、ProMetic Life-Sciences Inc(Canada)、BioLine Rx(Israel)、Genzyme Corporation(US) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アンジオテンシン変換酵素（ACE）阻害剤、ピルフェニドン、レニン阻害剤、アンジオテンシンII受容体遮断薬（ARB）、バソペプチダーゼ阻害剤 ・用途別分析2016年-2026年：慢性腎臓病、腎臓がん治療、その他 ・腎線維化治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・腎線維化治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・腎線維化治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・腎線維化治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・腎線維化治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Kidney Fibrosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Kidney Fibrosis Treatment size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Kidney Fibrosis Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Kidney Fibrosis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors

Market segment by Application, can be divided into
Chronic Kidney Diseases
Kidney Cancer Treatment
Others

Market segment by players, this report covers
Merck and Co(US)
Pfizer Inc(US)
F. Hoffman-La Roche(Switzerland)
InterMune Inc(US)
Galectin Therapeutics(US)
La Jolla Pharmaceutical Company(US)
ProMetic Life-Sciences Inc(Canada)
BioLine Rx(Israel)
Genzyme Corporation(US)

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Kidney Fibrosis Treatment
1.2 Classification of Kidney Fibrosis Treatment by Type
1.2.1 Overview: Global Kidney Fibrosis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Kidney Fibrosis Treatment Revenue Market Share by Type in 2020
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Pirfenidone
1.2.5 Renin Inhibitors
1.2.6 Angiotensin II Receptor Blockers (ARBs)
1.2.7 Vasopeptidase Inhibitors
1.3 Global Kidney Fibrosis Treatment Market by Application
1.3.1 Overview: Global Kidney Fibrosis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Chronic Kidney Diseases
1.3.3 Kidney Cancer Treatment
1.3.4 Others
1.4 Global Kidney Fibrosis Treatment Market Size & Forecast
1.5 Global Kidney Fibrosis Treatment Market Size and Forecast by Region
1.5.1 Global Kidney Fibrosis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Kidney Fibrosis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Kidney Fibrosis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Kidney Fibrosis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Kidney Fibrosis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Kidney Fibrosis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Kidney Fibrosis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Kidney Fibrosis Treatment Market Drivers
1.6.2 Kidney Fibrosis Treatment Market Restraints
1.6.3 Kidney Fibrosis Treatment Trends Analysis
2 Company Profiles
2.1 Merck and Co(US)
2.1.1 Merck and Co(US) Details
2.1.2 Merck and Co(US) Major Business
2.1.3 Merck and Co(US) Kidney Fibrosis Treatment Product and Solutions
2.1.4 Merck and Co(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Merck and Co(US) Recent Developments and Future Plans
2.2 Pfizer Inc(US)
2.2.1 Pfizer Inc(US) Details
2.2.2 Pfizer Inc(US) Major Business
2.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Product and Solutions
2.2.4 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Inc(US) Recent Developments and Future Plans
2.3 F. Hoffman-La Roche(Switzerland)
2.3.1 F. Hoffman-La Roche(Switzerland) Details
2.3.2 F. Hoffman-La Roche(Switzerland) Major Business
2.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product and Solutions
2.3.4 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 F. Hoffman-La Roche(Switzerland) Recent Developments and Future Plans
2.4 InterMune Inc(US)
2.4.1 InterMune Inc(US) Details
2.4.2 InterMune Inc(US) Major Business
2.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Product and Solutions
2.4.4 InterMune Inc(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 InterMune Inc(US) Recent Developments and Future Plans
2.5 Galectin Therapeutics(US)
2.5.1 Galectin Therapeutics(US) Details
2.5.2 Galectin Therapeutics(US) Major Business
2.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Product and Solutions
2.5.4 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Galectin Therapeutics(US) Recent Developments and Future Plans
2.6 La Jolla Pharmaceutical Company(US)
2.6.1 La Jolla Pharmaceutical Company(US) Details
2.6.2 La Jolla Pharmaceutical Company(US) Major Business
2.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product and Solutions
2.6.4 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 La Jolla Pharmaceutical Company(US) Recent Developments and Future Plans
2.7 ProMetic Life-Sciences Inc(Canada)
2.7.1 ProMetic Life-Sciences Inc(Canada) Details
2.7.2 ProMetic Life-Sciences Inc(Canada) Major Business
2.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product and Solutions
2.7.4 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 ProMetic Life-Sciences Inc(Canada) Recent Developments and Future Plans
2.8 BioLine Rx(Israel)
2.8.1 BioLine Rx(Israel) Details
2.8.2 BioLine Rx(Israel) Major Business
2.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Product and Solutions
2.8.4 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 BioLine Rx(Israel) Recent Developments and Future Plans
2.9 Genzyme Corporation(US)
2.9.1 Genzyme Corporation(US) Details
2.9.2 Genzyme Corporation(US) Major Business
2.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Product and Solutions
2.9.4 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Genzyme Corporation(US) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Kidney Fibrosis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Kidney Fibrosis Treatment Players Market Share
3.2.2 Top 10 Kidney Fibrosis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Kidney Fibrosis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Kidney Fibrosis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Kidney Fibrosis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Kidney Fibrosis Treatment Revenue Market Share by Application (2016-2021)
5.2 Kidney Fibrosis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Kidney Fibrosis Treatment Revenue by Type (2016-2026)
6.2 North America Kidney Fibrosis Treatment Revenue by Application (2016-2026)
6.3 North America Kidney Fibrosis Treatment Market Size by Country
6.3.1 North America Kidney Fibrosis Treatment Revenue by Country (2016-2026)
6.3.2 United States Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Kidney Fibrosis Treatment Revenue by Type (2016-2026)
7.2 Europe Kidney Fibrosis Treatment Revenue by Application (2016-2026)
7.3 Europe Kidney Fibrosis Treatment Market Size by Country
7.3.1 Europe Kidney Fibrosis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Kidney Fibrosis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Kidney Fibrosis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Kidney Fibrosis Treatment Market Size by Region
8.3.1 Asia-Pacific Kidney Fibrosis Treatment Revenue by Region (2016-2026)
8.3.2 China Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Kidney Fibrosis Treatment Revenue by Type (2016-2026)
9.2 South America Kidney Fibrosis Treatment Revenue by Application (2016-2026)
9.3 South America Kidney Fibrosis Treatment Market Size by Country
9.3.1 South America Kidney Fibrosis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Kidney Fibrosis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Kidney Fibrosis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Kidney Fibrosis Treatment Market Size by Country
10.3.1 Middle East & Africa Kidney Fibrosis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Kidney Fibrosis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Kidney Fibrosis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Kidney Fibrosis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Kidney Fibrosis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Kidney Fibrosis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Kidney Fibrosis Treatment Revenue Market Share by Region (2021-2026)
Table 6. Merck and Co(US) Corporate Information, Head Office, and Major Competitors
Table 7. Merck and Co(US) Major Business
Table 8. Merck and Co(US) Kidney Fibrosis Treatment Product and Solutions
Table 9. Merck and Co(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Inc(US) Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Inc(US) Major Business
Table 12. Pfizer Inc(US) Kidney Fibrosis Treatment Product and Solutions
Table 13. Pfizer Inc(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. F. Hoffman-La Roche(Switzerland) Corporate Information, Head Office, and Major Competitors
Table 15. F. Hoffman-La Roche(Switzerland) Major Business
Table 16. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product and Solutions
Table 17. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. InterMune Inc(US) Corporate Information, Head Office, and Major Competitors
Table 19. InterMune Inc(US) Major Business
Table 20. InterMune Inc(US) Kidney Fibrosis Treatment Product and Solutions
Table 21. InterMune Inc(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Galectin Therapeutics(US) Corporate Information, Head Office, and Major Competitors
Table 23. Galectin Therapeutics(US) Major Business
Table 24. Galectin Therapeutics(US) Kidney Fibrosis Treatment Product and Solutions
Table 25. Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. La Jolla Pharmaceutical Company(US) Corporate Information, Head Office, and Major Competitors
Table 27. La Jolla Pharmaceutical Company(US) Major Business
Table 28. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product and Solutions
Table 29. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. ProMetic Life-Sciences Inc(Canada) Corporate Information, Head Office, and Major Competitors
Table 31. ProMetic Life-Sciences Inc(Canada) Major Business
Table 32. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product and Solutions
Table 33. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. BioLine Rx(Israel) Corporate Information, Head Office, and Major Competitors
Table 35. BioLine Rx(Israel) Major Business
Table 36. BioLine Rx(Israel) Kidney Fibrosis Treatment Product and Solutions
Table 37. BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Genzyme Corporation(US) Corporate Information, Head Office, and Major Competitors
Table 39. Genzyme Corporation(US) Major Business
Table 40. Genzyme Corporation(US) Kidney Fibrosis Treatment Product and Solutions
Table 41. Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Kidney Fibrosis Treatment Revenue (USD Million) by Players (2019-2021)
Table 43. Global Kidney Fibrosis Treatment Revenue Share by Players (2019-2021)
Table 44. Breakdown of Kidney Fibrosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Kidney Fibrosis Treatment Players Head Office, Products and Services Provided
Table 46. Kidney Fibrosis Treatment Mergers & Acquisitions in the Past Five Years
Table 47. Kidney Fibrosis Treatment New Entrants and Expansion Plans
Table 48. Global Kidney Fibrosis Treatment Revenue (USD Million) by Type (2016-2021)
Table 49. Global Kidney Fibrosis Treatment Revenue Share by Type (2016-2021)
Table 50. Global Kidney Fibrosis Treatment Revenue Forecast by Type (2021-2026)
Table 51. Global Kidney Fibrosis Treatment Revenue by Application (2016-2021)
Table 52. Global Kidney Fibrosis Treatment Revenue Forecast by Application (2021-2026)
Table 53. North America Kidney Fibrosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Kidney Fibrosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Kidney Fibrosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Kidney Fibrosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Kidney Fibrosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Kidney Fibrosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Kidney Fibrosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Kidney Fibrosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Kidney Fibrosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Kidney Fibrosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Kidney Fibrosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Kidney Fibrosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Kidney Fibrosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Kidney Fibrosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Kidney Fibrosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Kidney Fibrosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Kidney Fibrosis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Kidney Fibrosis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Kidney Fibrosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Kidney Fibrosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Kidney Fibrosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Kidney Fibrosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Kidney Fibrosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Kidney Fibrosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Kidney Fibrosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Kidney Fibrosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Kidney Fibrosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Kidney Fibrosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Kidney Fibrosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Kidney Fibrosis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Kidney Fibrosis Treatment Picture
Figure 2. Global Kidney Fibrosis Treatment Revenue Market Share by Type in 2020
Figure 3. Angiotensin Converting Enzyme (ACE) Inhibitors
Figure 4. Pirfenidone
Figure 5. Renin Inhibitors
Figure 6. Angiotensin II Receptor Blockers (ARBs)
Figure 7. Vasopeptidase Inhibitors
Figure 8. Kidney Fibrosis Treatment Revenue Market Share by Application in 2020
Figure 9. Chronic Kidney Diseases Picture
Figure 10. Kidney Cancer Treatment Picture
Figure 11. Others Picture
Figure 12. Global Kidney Fibrosis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Kidney Fibrosis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Kidney Fibrosis Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Kidney Fibrosis Treatment Revenue Market Share by Region in 2020
Figure 16. North America Kidney Fibrosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Kidney Fibrosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Kidney Fibrosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Kidney Fibrosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Kidney Fibrosis Treatment Market Drivers
Figure 21. Kidney Fibrosis Treatment Market Restraints
Figure 22. Kidney Fibrosis Treatment Market Trends
Figure 23. Merck and Co(US) Recent Developments and Future Plans
Figure 24. Pfizer Inc(US) Recent Developments and Future Plans
Figure 25. F. Hoffman-La Roche(Switzerland) Recent Developments and Future Plans
Figure 26. InterMune Inc(US) Recent Developments and Future Plans
Figure 27. Galectin Therapeutics(US) Recent Developments and Future Plans
Figure 28. La Jolla Pharmaceutical Company(US) Recent Developments and Future Plans
Figure 29. ProMetic Life-Sciences Inc(Canada) Recent Developments and Future Plans
Figure 30. BioLine Rx(Israel) Recent Developments and Future Plans
Figure 31. Genzyme Corporation(US) Recent Developments and Future Plans
Figure 33. Global Kidney Fibrosis Treatment Revenue Share by Players in 2020
Figure 34. Kidney Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Kidney Fibrosis Treatment Revenue Market Share in 2020
Figure 36. Global Top 10 Players Kidney Fibrosis Treatment Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Kidney Fibrosis Treatment Revenue Share by Type in 2020
Figure 39. Global Kidney Fibrosis Treatment Market Share Forecast by Type (2021-2026)
Figure 40. Global Kidney Fibrosis Treatment Revenue Share by Application in 2020
Figure 41. Global Kidney Fibrosis Treatment Market Share Forecast by Application (2021-2026)
Figure 42. North America Kidney Fibrosis Treatment Sales Market Share by Type (2016-2026)
Figure 43. North America Kidney Fibrosis Treatment Sales Market Share by Application (2016-2026)
Figure 44. North America Kidney Fibrosis Treatment Revenue Market Share by Country (2016-2026)
Figure 45. United States Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Kidney Fibrosis Treatment Sales Market Share by Type (2016-2026)
Figure 49. Europe Kidney Fibrosis Treatment Sales Market Share by Application (2016-2026)
Figure 50. Europe Kidney Fibrosis Treatment Revenue Market Share by Country (2016-2026)
Figure 51. Germany Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Kidney Fibrosis Treatment Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Kidney Fibrosis Treatment Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Kidney Fibrosis Treatment Revenue Market Share by Region (2016-2026)
Figure 59. China Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Kidney Fibrosis Treatment Sales Market Share by Type (2016-2026)
Figure 66. South America Kidney Fibrosis Treatment Sales Market Share by Application (2016-2026)
Figure 67. South America Kidney Fibrosis Treatment Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Kidney Fibrosis Treatment Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Kidney Fibrosis Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Kidney Fibrosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

---